Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Capital Expenditures (2020 - 2025)

RxSight's Capital Expenditures history spans 6 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 77.47% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $3.8 million, down 29.6%, while the annual FY2025 figure was $3.8 million, 29.6% down from the prior year.
  • Capital Expenditures reached $1.1 million in Q4 2025 per RXST's latest filing, up from $581000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.0 million in Q4 2024 to a low of -$2.4 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $694250.0, with a median of $434000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: crashed 2196.77% in 2022, then surged 7008.45% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $1.8 million in 2021, then rose by 24.42% to $2.2 million in 2022, then tumbled by 96.83% to $71000.0 in 2023, then soared by 7008.45% to $5.0 million in 2024, then tumbled by 77.47% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Capital Expenditures are $1.1 million (Q4 2025), $581000.0 (Q3 2025), and $1.9 million (Q2 2025).